AAA today announced that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating 177Lutetium Dotatate, an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”).